Concord Biotech Secures USFDA Approval for Mycophenolate Mofetil Oral Suspension
Concord Biotech Ltd has announced that it has received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) covering Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.Mycophenolate mofetil is categorized as an antimetabolite immunosuppressant. It is indicated for the prophylaxis of organ rejection in adult and pediatric recipients aged 3 months and older following allogeneic kidney, heart, or liver transplants, used in combination with other immunosuppressants.
The approval is significant for the company's growth trajectory in the U.S. and international sectors. According to market estimates, the U.S. market for Mycophenolate Mofetil is approximately US$ 30 million. This approval is expected to enable Concord Biotech to enhance its product offerings and strengthen its position within the attractive U.S. market.
The key details concerning this regulatory approval are summarized below:
| Area | Detail |
|---|---|
| Regulatory Authority | U. S. Food &Drug Administration (USFDA) |
| Approval Secured | Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL |
| Strategic Impact | Strengthens the Company's position and aligns with its long-term growth strategy in the U.S. market. |
| Market Estimate | US$ 30 million |
CONCORDBIO Stock Price Movement
Today, Concord Biotech Limited shares gained 11.18% to close at ₹1166.2. The stock settled at this level on a volume of 1.86 million shares, indicating strong buying interest throughout the trading day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.